The mixed earnings report from ADC Therapeutics, with an EPS beat but a slight miss on sales, presents a neutral to slightly positive outlook. The EPS beat indicates operational efficiency or cost control, which investors may view positively. However, the slight miss on sales and the year-over-year decline could raise concerns about growth prospects. Given these factors, the short-term impact on ADCT's stock price is likely to be neutral, as positive sentiment from the EPS beat may be tempered by concerns over sales performance.